Expert Addresses Sequencing Challenges in HCC
Kabir Mody, MD, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma.
Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma (HCC).
This is a new era in HCC with regard to the amount of treatment options patients have, Mody says. The question now is how these agents should be sequenced.
There is not much data available yet, but some second-line trials have looked at patients who have progressed on sorafenib (Nexavar) to determine which agent can be used next. The CheckMate040 study also had a cohort of patients who had no prior systemic therapy prior to treatment with nivolumab (Opdivo). There are also a few first-line trials pending looking at immunotherapies.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
